{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T03:03:22Z","timestamp":1792638202225,"version":"4.5.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T00:00:00Z","timestamp":1694736000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis International AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008131","name":"University of Bonn","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008131","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006122","name":"Deutsche Ophthalmologische Gesellschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006122","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008792","name":"Novartis Pharma GmbH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","aaojournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.ophtha.2023.09.006","type":"journal-article","created":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T12:59:32Z","timestamp":1694523572000},"page":"161-178","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"title":["Single Center Experience with Voretigene Neparvovec Gene Augmentation Therapy in RPE65 Mutation\u2013Associated Inherited Retinal Degeneration in a Clinical Setting"],"prefix":"10.1016","volume":"131","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9737-8127","authenticated-orcid":false,"given":"Birgit","family":"Lorenz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine H.","family":"K\u00fcnzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus N.","family":"Preising","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna P.","family":"Scholz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petrus","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank G.","family":"Holz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ophtha.2023.09.006_bib1","first-page":"2735","article-title":"Early-onset severe rod-cone dystrophy in young children with RPE65 mutations","volume":"41","author":"Lorenz","year":"2000","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2023.09.006_bib2","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/ceo.13022","article-title":"Novel mobility test to assess functional vision in patients with inherited retinal dystrophies","volume":"46","author":"Chung","year":"2018","journal-title":"Clin Exp Ophthalmol"},{"key":"10.1016\/j.ophtha.2023.09.006_bib3","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1159\/000515688","article-title":"Current management of patients with RPE65 mutation-associated inherited retinal degenerations in Europe: results of a multinational survey by the European Vision Institute Clinical Research Network","volume":"64","author":"Lorenz","year":"2021","journal-title":"Ophthalmic Res"},{"key":"10.1016\/j.ophtha.2023.09.006_bib4","doi-asserted-by":"crossref","first-page":"13658","DOI":"10.1073\/pnas.0504167102","article-title":"Mutation of key residues of RPE65 abolishes its enzymatic role as isomerohydrolase in the visual cycle","volume":"102","author":"Redmond","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ophtha.2023.09.006_bib5","doi-asserted-by":"crossref","first-page":"5235","DOI":"10.1167\/iovs.07-1671","article-title":"A\u00a0comprehensive clinical and biochemical functional study of a novel RPE65 hypomorphic mutation","volume":"49","author":"Lorenz","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2023.09.006_bib6","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1136\/bjophthalmol-2015-308019","article-title":"Preserved visual function in retinal dystrophy due to hypomorphic RPE65 mutations","volume":"100","author":"Hull","year":"2016","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2023.09.006_bib7","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/j.ophtha.2004.01.033","article-title":"Lack of fundus autofluorescence to 488 nanometers from childhood on in patients with early-onset severe retinal dystrophy associated with mutations in RPE65","volume":"111","author":"Lorenz","year":"2004","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2023.09.006_bib8","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(17)31868-8","article-title":"Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial","volume":"390","author":"Russell","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ophtha.2023.09.006_bib9","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.ophtha.2019.06.017","article-title":"Efficacy, safety, and durability of voretigene neparvovec-rzyl in RPE65 mutation-associated inherited retinal dystrophy: results of phase 1 and 3 trials","volume":"126","author":"Maguire","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2023.09.006_bib10","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/j.ophtha.2021.03.031","article-title":"Durability of voretigene neparvovec for biallelic RPE65-mediated inherited retinal disease: phase 3 results at 3 and 4 years","volume":"128","author":"Maguire","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2023.09.006_bib11","article-title":"Current management of patients with RPE65 mutation-associated inherited retinal degenerations (RPE65-IRD) in Europe. Results of a 2-year follow-up multinational survey","author":"Lorenz","year":"2023","journal-title":"Ophthalmic Res"},{"key":"10.1016\/j.ophtha.2023.09.006_bib12","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-021-01807-3","article-title":"Frequency and phenotypic characteristics of RPE65 mutations in the Chinese population","volume":"16","author":"Gao","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.ophtha.2023.09.006_bib13","first-page":"2326","article-title":"Clinical exome sequencing facilitates the understanding of genetic heterogeneity in Leber congenital amaurosis patients with variable phenotype in southern India","volume":"8","author":"Viswarubhiny","year":"2021","journal-title":"Eye Vis (Lond)"},{"key":"10.1016\/j.ophtha.2023.09.006_bib14","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1167\/iovs.12-11341","article-title":"Intervisit variability of visual parameters in Leber congenital amaurosis caused by RPE65 mutations","volume":"54","author":"Roman","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2023.09.006_bib15","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-22180-6","article-title":"Visual function and retinal changes after voretigene neparvovec treatment in children with biallelic RPE65-related inherited retinal dystrophy","volume":"12","author":"Testa","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.ophtha.2023.09.006_bib16","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3390\/biomedicines11010103","article-title":"Gene therapy with voretigene neparvovec improves vision and partially restores electrophysiological function in pre-school children with Leber congenital amaurosis","volume":"11","author":"Gerhardt","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.ophtha.2023.09.006_bib17","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.oret.2021.03.016","article-title":"Perifoveal chorioretinal atrophy after subretinal voretigene neparvovec-rzyl for RPE65-mediated Leber congenital amaurosis","volume":"6","author":"Gange","year":"2022","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.ophtha.2023.09.006_bib18","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.oret.2021.11.005","article-title":"Visual acuity, retinal morphology, and patients\u2019 perceptions after voretigene neparovec-rzyl therapy for RPE65-associated retinal disease","volume":"6","author":"Sengillo","year":"2022","journal-title":"Ophthalmol Retina"},{"issue":"9","key":"10.1016\/j.ophtha.2023.09.006_bib19","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1136\/bjophthalmol-2021-321023","article-title":"Development of retinal atrophy after subretinal gene therapy with voretigene neparvovec","volume":"107","author":"Reichel","year":"2023","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2023.09.006_bib20","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1007\/s00417-021-05508-2","article-title":"Real-world outcomes of voretigene neparvovec treatment in pediatric patients with RPE65-associated Leber congenital amaurosis","volume":"260","author":"Deng","year":"2022","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ophtha.2023.09.006_bib21","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.ophtha.2022.06.018","article-title":"Inflammation after voretigene neparvovec administration in patients with RPE65-related retinal dystrophy","volume":"129","author":"Kessel","year":"2022","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2023.09.006_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2020.100915","article-title":"Immune responses to retinal gene therapy using adeno-associated viral vectors - Implications for treatment success and safety","volume":"83","author":"Bucher","year":"2021","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.ophtha.2023.09.006_bib23","first-page":"a041307","article-title":"Lessons learned from the development of the first FDA-approved gene therapy drug, voretigene neparvovec-rzyl","author":"Bennett","year":"2022","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.ophtha.2023.09.006_bib24","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1001\/jamaophthalmol.2019.2512","article-title":"Cost-effectiveness of voretigene neparvovec-rzyl vs standard care for RPE65-mediated inherited retinal disease","volume":"137","author":"Johnson","year":"2019","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ophtha.2023.09.006_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1167\/tvst.9.9.17","article-title":"Cost effectiveness of voretigene neparvovec for RPE65-mediated inherited retinal degeneration in Germany","volume":"9","author":"Uhrmann","year":"2020","journal-title":"Transl Vis Sci Technol"},{"key":"10.1016\/j.ophtha.2023.09.006_bib26","first-page":"11","article-title":"A Systematic review and meta-analyses of interventional clinical trial studies for gene therapies for the inherited retinal degenerations (IRDs)","author":"Tuohy","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.ophtha.2023.09.006_bib27","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-020-1304-1","article-title":"The effect of human gene therapy for RPE65-associated Leber\u2019s congenital amaurosis on visual function: a systematic review and meta-analysis","volume":"15","author":"Wang","year":"2020","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.ophtha.2023.09.006_bib28","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1136\/bjophthalmol-2020-318286","article-title":"Spatial and temporal resolution of the photoreceptors rescue dynamics after treatment with voretigene neparvovec","volume":"106","author":"Stingl","year":"2022","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2023.09.006_bib29","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ajo.2018.09.024","article-title":"The natural history of inherited retinal dystrophy due to biallelic mutations in the RPE65 gene","volume":"199","author":"Chung","year":"2019","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2023.09.006_bib30","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00417-004-1020-x","article-title":"Longitudinal and cross-sectional study of patients with early-onset severe retinal dystrophy associated with RPE65 mutations","volume":"243","author":"Paunescu","year":"2005","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ophtha.2023.09.006_bib31","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s00417-008-0926-0","article-title":"Resolving the clinical acuity categories \u201chand motion\u201d and \u201ccounting fingers\u201d using the Freiburg Visual Acuity Test (FrACT)","volume":"247","author":"Lange","year":"2009","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ophtha.2023.09.006_bib32","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1007\/s00417-002-0502-y","article-title":"Phenotypes of 16 Stargardt macular dystrophy\/fundus flavimaculatus patients with known ABCA4 mutations and evaluation of genotype-phenotype correlation","volume":"240","author":"Gerth","year":"2002","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ophtha.2023.09.006_bib33","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.exer.2004.09.008","article-title":"Quantifying rod photoreceptor-mediated vision in retinal degenerations: dark-adapted thresholds as outcome measures","volume":"80","author":"Roman","year":"2005","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.ophtha.2023.09.006_bib34","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s10633-009-9204-7","article-title":"Psychophysical assessment of low visual function in patients with retinal degenerative diseases (RDDs) with the Diagnosys full-field stimulus threshold (D-FST)","volume":"119","author":"Klein","year":"2009","journal-title":"Doc Ophthalmol"},{"key":"10.1016\/j.ophtha.2023.09.006_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1167\/tvst.9.11.9","article-title":"The RUSH2A Study: best-corrected visual acuity, full-field electroretinography amplitudes, and full-field stimulus thresholds at baseline","volume":"9","author":"Birch","year":"2020","journal-title":"Transl Vis Sci Technol"},{"key":"10.1016\/j.ophtha.2023.09.006_bib36","series-title":"ggplot2: Elegant Graphics for Data Analysis","author":"Wickham","year":"2016"},{"key":"10.1016\/j.ophtha.2023.09.006_bib37","unstructured":"R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria;\u00a02022."},{"key":"10.1016\/j.ophtha.2023.09.006_bib38","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"},{"key":"10.1016\/j.ophtha.2023.09.006_bib39","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.omtm.2023.02.006","article-title":"Intravitreal air tamponade after AAV2 subretinal injection modifies retinal EGFP\u00a0distribution","volume":"28","author":"Ducloyer","year":"2023","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.ophtha.2023.09.006_bib40","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-32667-w","article-title":"Examining the role of cone-expressed RPE65 in mouse cone function","volume":"8","author":"Kolesnikov","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.ophtha.2023.09.006_bib41","doi-asserted-by":"crossref","DOI":"10.1136\/bjo-2022-321488","article-title":"Subretinal deposits in young patients treated with voretigene neparvovec-rzyl for RPE65-mediated retinal dystrophy","author":"Lopez","year":"2023","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2023.09.006_bib42","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1167\/tvst.12.4.17","article-title":"Improved rod sensitivity as assessed by two-color dark-adapted perimetry in patients\u00a0with RPE65-related retinopathy treated with voretigene neparvovec-rzyl","volume":"12","author":"Ku","year":"2023","journal-title":"Transl Vis Sci Technol"},{"issue":"7","key":"10.1016\/j.ophtha.2023.09.006_bib43","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.ophtha.2023.02.015","article-title":"Full-field scotopic threshold improvement following voretigene neparvovec-rzyl treatment correlates with chorioretinal atrophy","volume":"130","author":"Stingl","year":"2023","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2023.09.006_bib44","doi-asserted-by":"crossref","first-page":"3088","DOI":"10.1073\/pnas.95.6.3088","article-title":"Mutations in the RPE65 gene in patients with autosomal recessive retinitis pigmentosa or Leber congenital amaurosis","volume":"95","author":"Morimura","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ophtha.2023.09.006_bib45","doi-asserted-by":"crossref","first-page":"5641","DOI":"10.1167\/iovs.12-9974","article-title":"Chromatic pupillometry dissects function of the three different light-sensitive retinal cell populations in RPE65 deficiency","volume":"53","author":"Lorenz","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2023.09.006_bib46","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/ng1097-194","article-title":"Mutations in RPE65 cause autosomal recessive childhood-onset severe retinal dystrophy","volume":"17","author":"Gu","year":"1997","journal-title":"Nat Genet"},{"key":"10.1016\/j.ophtha.2023.09.006_bib47","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1152\/physiolgenomics.00096.2016","article-title":"Genetic analysis of 10 pedigrees with inherited retinal degeneration by exome sequencing and phenotype-genotype association","volume":"49","author":"Biswas","year":"2017","journal-title":"Physiol Genomics"}],"updated-by":[{"DOI":"10.1016\/j.ophtha.2024.02.021","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000}}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642023006310?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642023006310?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T14:45:35Z","timestamp":1719067535000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642023006310"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S0161642023006310"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2023.09.006","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.ophtha.2024.02.021","asserted-by":"object"}]},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Single Center Experience with Voretigene Neparvovec Gene Augmentation Therapy in RPE65 Mutation\u2013Associated Inherited Retinal Degeneration in a Clinical Setting","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2023.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by the American Academy of Ophthalmology.","name":"copyright","label":"Copyright"}]}}